These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Recent advances in antiarrhythmic drug treatment of atrial fibrillation. Polovina MM; Potpara TS Recent Pat Cardiovasc Drug Discov; 2013 Aug; 8(2):112-26. PubMed ID: 23795692 [TBL] [Abstract][Full Text] [Related]
46. Unraveling the Role of K Mondéjar-Parreño G Front Biosci (Schol Ed); 2022 Nov; 14(4):31. PubMed ID: 36575841 [TBL] [Abstract][Full Text] [Related]
47. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236 [TBL] [Abstract][Full Text] [Related]
48. Electrical, contractile and structural remodeling during atrial fibrillation. Allessie M; Ausma J; Schotten U Cardiovasc Res; 2002 May; 54(2):230-46. PubMed ID: 12062329 [TBL] [Abstract][Full Text] [Related]
50. New directions in antiarrhythmic drug therapy for atrial fibrillation. Heijman J; Voigt N; Dobrev D Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476 [TBL] [Abstract][Full Text] [Related]
51. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. Nattel S; Harada M J Am Coll Cardiol; 2014 Jun; 63(22):2335-45. PubMed ID: 24613319 [TBL] [Abstract][Full Text] [Related]
52. In silico screening of the key cellular remodeling targets in chronic atrial fibrillation. Koivumäki JT; Seemann G; Maleckar MM; Tavi P PLoS Comput Biol; 2014 May; 10(5):e1003620. PubMed ID: 24853123 [TBL] [Abstract][Full Text] [Related]
53. Atrial remodeling: new pathophysiological mechanism of atrial fibrillation. Xu Y; Sharma D; Li G; Liu Y Med Hypotheses; 2013 Jan; 80(1):53-6. PubMed ID: 23148964 [TBL] [Abstract][Full Text] [Related]
54. New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation. Aguilar M; Rose RA; Takawale A; Nattel S; Reilly S Cardiovasc Res; 2021 Jun; 117(7):1645-1661. PubMed ID: 33723575 [TBL] [Abstract][Full Text] [Related]
55. Pharmacologic management of atrial fibrillation: current therapeutic strategies. Lévy S Am Heart J; 2001 Feb; 141(2 Suppl):S15-21. PubMed ID: 11174354 [TBL] [Abstract][Full Text] [Related]
56. Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation. Seki M; LaCanna R; Powers JC; Vrakas C; Liu F; Berretta R; Chacko G; Holten J; Jadiya P; Wang T; Arkles JS; Copper JM; Houser SR; Huang J; Patel VV; Recchia FA J Pharmacol Exp Ther; 2016 Sep; 358(3):441-9. PubMed ID: 27353074 [TBL] [Abstract][Full Text] [Related]
57. Chronic B-Type Natriuretic Peptide Therapy Prevents Atrial Electrical Remodeling in a Rabbit Model of Atrial Fibrillation. Zhao H; Li T; Liu G; Zhang L; Li G; Yu J; Lou Q; He R; Zhan C; Li L; Yang W; Zang Y; Cheng C; Li W J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):575-585. PubMed ID: 31159577 [TBL] [Abstract][Full Text] [Related]
59. Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors. Tanaka H; Tatsumi K; Matsuzoe H; Soga F; Matsumoto K; Hirata KI Int J Cardiovasc Imaging; 2021 Apr; 37(4):1333-1341. PubMed ID: 33392879 [TBL] [Abstract][Full Text] [Related]
60. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]